Skip to main content
Signal8

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. is a clinical-stage life sciences firm dedicated to discovering and advancing anti-fibrotic and anti-inflammatory therapies for cardiovascular disease (CVD). Its leading candidate, CardiolRx, is currently undergoing a multi-national, randomized, double-blind, placebo-controlled Phase II/III study. This pivotal trial assesses CardiolRx's safety and effectiveness as a cardioprotective treatment to diminish cardiovascular and respiratory complications in hospitalized COVID-19 patients, while also investigating its potential for acute myocarditis. Furthermore, the company is developing a subcutaneous version of CardiolRx, aimed at addressing the cardiac fibrosis and inflammation linked to the onset and progression of heart failure. Cardiol Therapeutics Inc. was established in 2017 and operates from its headquarters in Oakville, Canada.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Drug Manufacturers - Specialty & Generic

Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc.

NASDAQ:CRDLHealthcare
-7.12%$0.8824
Mkt Cap$112.68M
EV-
Float112.16M
O/S127.69M
VOL526K sh
$ Vol$471K
RVOL1.00×
Inst Own31.9%
Net Cash/Sh-
Dilution
Cardiol Therapeutics Inc. logoNASDAQ:CRDL$0.8824-7.12%
Short interest (FINRA)
Not computed: short interest % needs a single float figure, and the float on record is a bound or estimate.
Oct 30 (20d)
2.6M
Oct 30 (20d)prev 2.8M▼ 8.7%
4.27
Oct 30 (20d)prev 1.30▲ 228.5%
Borrow

The cost to borrow CRDL shares for a short sale and how many shares are available to borrow, refreshed through the session.

Borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
27.7%
Nov 18 (1d)prev 20.3%▲ 7.4 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

5.3K
Oct 30 (20d)prev 7.6K▼ 29.8%
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Fails to deliver24 settlement dates
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20262.6M sh
Oct 15, 20262.8M sh
Sep 30, 20263.1M sh
Sep 15, 20263.3M sh
Aug 31, 20262.9M sh
Latest fails to deliver
DateShares failed
Oct 30, 20265.3K sh
Oct 27, 20267.6K sh
Oct 23, 20264.8K sh
Oct 22, 202636.9K sh
Oct 20, 20269.0K sh

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 18
Latest sessions
DateReported short
Nov 18, 202627.7%
Nov 17, 202620.3%
Nov 16, 202658.0%
Nov 13, 202627.5%
Nov 12, 202637.4%
91-session median 47.7%mean 45.9%range 3.2–76.0%

130 calendar days requested; 92 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for CRDL: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 2,596,228 CRDL shares were sold short (4.27 days to cover).